The Documentation of the Effects on Quality of Life (QOL) and Working Productivity and Activity Impairment (WPAI) in Patients With Rheumatoid Arthritis (RA) Under HUMIRA® (Adalimumab) in Routine Clinical Practice

Trial Profile

The Documentation of the Effects on Quality of Life (QOL) and Working Productivity and Activity Impairment (WPAI) in Patients With Rheumatoid Arthritis (RA) Under HUMIRA® (Adalimumab) in Routine Clinical Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Apr 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ANOUVEAU
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 31 Jan 2017 Results assessing effect of adalimumab on RA-related WPAI in Japanese patients with RA published in the Advances in Therapy.
    • 25 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 04 Nov 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top